Cancer Stem Cell - a new resource for tumor initiating cell based assays
Stay on the cutting edge- defining cancer stem cells.Recent evidence suggests that a subset of cells within a tumor have 'stem-like' characteristics. These tumor-initiating cells, distinct from non-malignant stem cells, show low proliferative rates, high self-renewing capacity, propensity to differentiate into actively proliferating tumor cells, resistance to chemotherapy or radiation, and are relatively resistant to standard therapy.
Cancer Stem Cells (CSC), also thought of as tumor initiating cells, have altered the landscape of cancer research. Understanding the molecular biology of cancer cells is now essential for developing more effective cancer treatments. Current strategies may include drugs targeting for apoptosis or alternatively determining agents or treatment regimens that enhance sensitivity of these therapy-resistant 'tumor stem cells' to the current or emerging anti-tumor drugs.
CrownBio's HuPrimeTM platform is the eminent resource as the world's largest collection of human primary tumor tissues for cutting edge discovery and the effect of anti-cancer therapeutics on tumor regrowth.
In vitro culture of cancer stem-like cells
Cancer Stem Cells (CSCs) comprise a unique subpopulation of neoplastic cells within tumors that is highly tumorigenic and relatively resistant to standard therapy. Accordingly, in order to overcome these traditional pitfalls, CrownBio is building a high quality resource enabling drug sensitivity testing and research that could target and eradicate CSCs.